How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

With over 18,000 tokens tracked across centralized and decentralized exchanges, the entire crypto market is worth nearly $3 trillion. This is 31% lower from the all-time high of $4.37 trillion in ...

Nvidia's restraint — focusing on enabling the ecosystem rather than owning it — has helped cement its role as the ...

In this Monday edition of quantum computing news, we look at a new push by SEALSQ ($LAES) to build silicon-based quantum systems, Xanadu’s early ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

Troy Segal is an editor and writer. She has 20+ years of experience covering personal finance, wealth management, and business news. David Kindness is a Certified Public Accountant (CPA) and an expert ...

Micah Castelo is a web editor for EdTech: Focus on K-12. Her experience includes education and community news coverage for the Syracuse Post-Standard and international news reporting for the Pulitzer ...

Some of the Capital One offers mentioned below are not currently available. Terms apply to American Express benefits and offers. Visit americanexpress.com to learn more. There are a lot of perks that ...